Q-omics provides the consensus-scored PTMAP4 profile across patient tissues and cancer cell-line models. PTMAP4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PTMAP4 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, PTMAP4 RNA expression shows 17,366 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, KICH, and KIRP as cancer lineages where PTMAP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTMAP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTMAP4 survival associations across molecular data types. PTMAP4 RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTMAP4 RNA expression–survival associations across cancer types. High PTMAP4 expression shows unfavorable associations in ACC, KIRP, LIHC and PAAD, but favorable associations in COAD and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PTMAP4 RNA expression.
This table summarizes PTMAP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PTMAP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTMAP4 shows lower tumor expression in KICH and higher tumor expression in LIHC, COAD, LUSC, HNSC and STAD. The KICH box plot shows higher PTMAP4 RNA expression in normal versus tumor tissue (log2 FC = −1.465, t-test p < 0.001).
This table shows molecular features associated with PTMAP4 in patient tissues and cancer cell lines. In patient samples, PTMAP4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
